SeraCare's CSO Mark Manak accents global blood safety.

The article presents information about Boston Biomedica Inc. (BBI). In late 2002, the U.S. Food and Drug Administration challenged diagnostic manufacturers to develop a blood-screening test for West Nile virus (WNV), and BBI quickly introduced quantitated WNV nucleic acid panels, which were provided to kit manufacturers to help them develop and validate their assays. When the first kits were introduced for IND investigations within months, BBI had the first set of well-characterized controls to monitor kit performance and consistency and to ensure continued test reliability.